- Home
- SPFI vs SIGA Comparison
SPFI vs SIGA Comparison
Compare SPFI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | SIGA |
|---|---|---|
| Founded | 1941 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.0M | 421.8M |
| IPO Year | 2019 | 1997 |
Fundamental Metrics
Financial Performance| Metric | SPFI | SIGA |
|---|---|---|
| Price | $38.88 | $6.19 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $41.50 | N/A |
| AVG Volume (30 Days) | 42.4K | ★ 455.0K |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | 1.64% | ★ 9.68% |
| EPS Growth | ★ 36.91 | N/A |
| EPS | ★ 3.51 | 1.03 |
| Revenue | ★ $205,251,000.00 | $172,249,641.00 |
| Revenue This Year | $13.52 | N/A |
| Revenue Next Year | $6.28 | $132.36 |
| P/E Ratio | $11.10 | ★ $6.02 |
| Revenue Growth | ★ 11.60 | N/A |
| 52 Week Low | $30.01 | $4.95 |
| 52 Week High | $42.38 | $9.62 |
Technical Indicators
Market Signals| Indicator | SPFI | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 39.45 |
| Support Level | $37.39 | $5.85 |
| Resistance Level | $39.50 | $6.15 |
| Average True Range (ATR) | 0.81 | 0.22 |
| MACD | 0.20 | 0.11 |
| Stochastic Oscillator | 76.12 | 71.88 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.